Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 392

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 392
---
 members of the Company’s executive management upon vesting of restricted stock units. During the year ended December 31, 2023, the Company issued123,000 shares of its common stock to members of the Company’s executive management and 10,000 shares to directors of the Company, upon vesting of restricted stock units.Warrant ExercisesDuring the year ended December 31, 2023, the Company issued 3,000 shares of its common stock to members of the Company’s executive management and 64,000 shares to a director of the Company, upon exercise of outstanding warrants.F-142
KINETA, INC. Notes to Consolidated Financial Statements 15. Segment Reporting The Company operates as a single reportable segment, which is primarily engaged in the development of next-generation immunotherapies. The Company has concluded that its President is the chief operating decision maker (“CODM”) for the year ended December 31, 2024 and its former CEO and President together were the CODM for the year ended December 31, 2023. The CODM reviews the Company’s performance and allocates resources on a consolidated basis. As a result, all financial information is disclosed in accordance with ASC 280-10for a single reportable segment. Basis of Presentation The accounting policies of the segment are the same as those described in the summary of significant accounting policies. Segment information is prepared on the same basis that the CODM uses for internal management reporting. Segment Information The following table presents information about the Company’s segment for the years ended December 31, 2024 and 2023:

|                               |     | Years Ended    
 December 31,   
 2024           
 (in thousands) |         |   |     | 2023 |         |   |
|:------------------------------|:----|:---------------|--------:|:--|:----|:-----|--------:|:--|
| Revenue                       |     | $              |       — |   |     | $    |   5,442 |   |
| Operating Loss                |     | $              | (13,532 | ) |     | $    | (15,723 | ) |
| Segment Assets                |     | $              |   1,019 |   |     | $    |  10,281 |   |
| Capital Expenditures          |     | $              |       — |   |     | $    |       — |   |
| Depreciation and Amortization |